Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 24, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results.
馬薩諸塞州劍橋--(美國商業資訊)--2024年4月24日--罕見病精準遺傳醫學領域的領導者Sarepta Therapeutics, Inc.（納斯達克股票代碼：SRPT）將在納斯達克全球市場於2024年5月1日星期三收盤後公佈2024年第一季度財務業績。隨後，在美國東部時間下午 4:30，該公司將舉行電話會議，討論其2024年第一季度的財務業績。
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
該活動將在Sarepta網站的投資者關係欄目下進行網絡直播 https://investorrelations.sarepta.com/events-presentations 活動結束後，重播將在那裏存檔一年。通過電話參與的有興趣的人士需要使用以下方式進行註冊 這個在線表格。註冊撥入詳細信息後，所有電話參與者將收到一封自動生成的電子郵件，其中包含撥入號碼的鏈接以及用於通過電話訪問活動的個人 PIN 碼。
About Sarepta Therapeutics
關於 Sarepta Therapeu
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
薩雷普塔正在執行一項緊急任務：爲摧毀生命和縮短未來的罕見疾病設計精準遺傳醫學。我們在杜興氏肌營養不良症（DMD）和肢節型肌營養不良症（LGMD）領域處於領導地位，目前我們有40多個項目處於不同的開發階段。我們龐大的產品線由我們在基因治療、RNA 和基因編輯領域的多平台精準遺傳醫學引擎驅動。欲了解更多信息，請訪問 www.sarepta.com 或者關注我們 領英， X（前身爲 Twitter）， Instagram 和 Facebook。
Internet Posting of Information
在互聯網上發佈信息
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
我們會定期在我們網站的 “投資者專區” 部分發布可能對投資者重要的信息，網址爲www.sarepta.com。我們鼓勵投資者和潛在投資者定期訪問我們的網站以獲取有關我們的重要信息。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424210170/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
投資者聯繫人：
伊恩·埃斯特潘，617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
媒體聯繫人：
特雷西·索倫蒂諾，617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
來源：Sarepta Therapeutics, Inc.
譯文內容由第三人軟體翻譯。